
Scibase Q2'24 - Steps towards a US Breakthrough

Redeye saw a Q2 report in which sales and gross margins did not deviate much from our expectations, while costs due to the increased pace in the US were higher. It is clear the pace of the efforts has increased. We have slightly adjusted our estimates downward for 2024/25e based on higher cost expectations and uncertainty about the timing of a breakthrough in the US. We maintain our Base case of SEK 2.8(2.8) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scibase Q2'24 - Steps towards a US Breakthrough](#)